ERBB2 and breast carcinoma: The present study showed that IG NAX014 administration (i) delays the development of spontaneous mammary tumors in HER-2/neu transgenic mice without negative effects on health and survival; (ii) inhibits breast cancer cell migration and metastasis in vitro and in vivo; (iii) induces in vitro and in vivo tumor cells senescence; and (iv) decreases TNF-α and VEGF plasma levels.